📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Fortis Healthcare Completes Merger of Four Subsidiaries into Fortis Hospitals
Fortis Healthcare has announced that the merger of four of its wholly-owned subsidiaries into Fortis Hospitals Limited (FHsL) became effective on March 1, 2026. The entities absorbed include Fortis Emergency Services, Fortis Cancer Care, Fortis Health Management (East), and Birdie & Birdie Realtors. This consolidation follows the filing of certified NCLT orders from the Delhi and Chandigarh benches with the Registrar of Companies. The move is designed to simplify the corporate structure and enhance operational efficiency across the group.
Key Highlights
Merger of four wholly-owned subsidiaries (FESL, FCCL, FHMEL, and B&B) into Fortis Hospitals Limited is now effective.
The effective date of the Scheme of Arrangement is confirmed as March 1, 2026.
NCLT orders from Delhi and Chandigarh benches were filed via Form INC-28 with the ROC.
The restructuring aims to reduce administrative overheads and streamline the organizational hierarchy.
💼 Action for Investors
Investors should view this as a positive administrative cleanup that simplifies the company's complex subsidiary structure. No immediate portfolio changes are necessary as the entities were already 100% owned.
Fortis Healthcare Q3 FY26: EBITDA Jumps 34.8%, Margin Expands to 22.3% Amid Strategic Acquisitions
Fortis Healthcare reported a strong Q3 FY26 with consolidated revenues growing 17.5% YoY to INR 2,265 crores, driven by a 19.4% growth in the hospital segment. Operating EBITDA surged 34.8% to INR 505 crores, reflecting significant margin expansion to 22.3% from 19.4% YoY. While reported PAT dipped to INR 197 crores due to a one-off INR 55 crore labor code expense, operational performance remained robust with ARPOB rising 4.5% to INR 2.56 crores. The company continues its aggressive expansion, recently acquiring People Tree Hospital in Bengaluru for INR 430 crores and adding 750 beds during the year.
Key Highlights
Consolidated EBITDA grew 34.8% YoY to INR 505 crores with margins expanding 290 bps to 22.3%.
Hospital business revenue increased 19.4% to INR 1,938 crores, supported by a 4.5% rise in ARPOB to INR 2.56 crores.
Acquired 125-bedded People Tree Hospital in Bengaluru for INR 430 crores with plans to expand to 300 beds.
Agilus Diagnostics reported a sharp margin improvement to 23.1% from 14.4% in the previous year.
Net debt stands at INR 2,547 crores (1.24x Net Debt/EBITDA) following recent inorganic growth investments.
💼 Action for Investors
Investors should focus on the strong operational margin expansion and the successful integration of new acquisitions. The temporary dip in PAT due to labor code provisions is a non-recurring item, making the core business growth trajectory attractive.
Fortis Promoter NTK Amends ₹10,930 Crore Lawsuit Against Daiichi Sankyo in Japan
Northern TK Venture (NTK), the promoter of Fortis Healthcare and a subsidiary of IHH Healthcare, has amended its legal claim against Daiichi Sankyo in the Tokyo District Court. NTK is seeking damages totaling approximately INR 10,930 Crores for losses related to tortious claims and defamation. The latest amendment seeks to prevent Daiichi Sankyo from obstructing future investments or corporate actions in Fortis and Fortis Malar through defamatory statements to SEBI. This legal action follows the successful completion of the mandatory open offers in November 2025.
Key Highlights
NTK filed a petition to amend its claim against Daiichi Sankyo in the Tokyo District Court on February 12, 2026.
The total claim amount for tortious losses stands at INR 109,299,359,054 (approx. INR 10,930 Crores).
The amendment aims to restrain Daiichi Sankyo from obstructing future corporate exercises or share acquisitions in Fortis.
This litigation follows the completion of IHH's mandatory open offers for Fortis and Malar on November 10, 2025.
💼 Action for Investors
Investors should monitor the progress of this litigation as it affects the promoter's ability to conduct future corporate actions without interference. While it doesn't impact daily operations, the massive claim amount and the attempt to secure injunctive relief are significant for long-term strategic stability.
Fortis Q3 Standalone Revenue Rises 20.7% YoY to ₹443 Cr; New ESOP Scheme Approved
Fortis Healthcare reported a 20.7% YoY growth in standalone revenue from operations to ₹442.93 crore for the quarter ended December 31, 2025. However, standalone net profit declined by 28.2% YoY to ₹28.40 crore, primarily due to a significant spike in finance costs and professional fees. The board has also approved a new Employee Stock Option Scheme (ESOP 2026) covering 1.51 crore shares to incentivize talent. Investors should note that legal overhangs regarding past promoter transactions and SFIO investigations remain ongoing.
Key Highlights
Standalone Revenue from operations increased to ₹44,293 lacs from ₹36,687 lacs in the previous year's quarter.
Standalone Net Profit for Q3 FY26 stood at ₹2,840 lacs compared to ₹3,956 lacs in Q3 FY25.
Finance costs more than doubled YoY, rising from ₹2,651 lacs to ₹5,566 lacs in the current quarter.
Board approved ESOP 2026 scheme with a pool of 1,50,99,163 options, each convertible into one equity share.
Ongoing SFIO investigations and Supreme Court-directed forensic audits regarding RHT Health Trust transactions continue to be monitored.
💼 Action for Investors
While top-line growth is healthy, investors should monitor the rising finance costs and the impact of the new ESOP scheme on equity dilution. The long-term legal risks associated with past promoter actions remain a critical factor for the stock's valuation.
Fortis Q3 FY26: Revenue up 17.5% to ₹2,265 Cr, Operating EBITDA jumps 34.8%
Fortis Healthcare reported a strong operational performance for Q3 FY26, with consolidated revenues growing 17.5% YoY to ₹2,265 crore. Operating EBITDA saw a significant jump of 34.8% to ₹505 crore, driven by margin expansion in both hospital (21.7%) and diagnostic (23.1%) segments. While reported PAT was impacted by a one-time exceptional loss of ₹45.9 crore related to new labor codes, the core business remains robust with a 14% increase in occupied beds. The company also expanded its footprint by acquiring People Tree Hospital in Bengaluru for ₹430 crore in January 2026.
Key Highlights
Consolidated Operating EBITDA grew 34.8% YoY to ₹505 Cr with margins expanding to 22.3% from 19.4%.
Hospital business revenue rose 19.4% to ₹1,938 Cr, supported by a 14% increase in occupied beds and higher ARPOB of ₹2.56 Cr.
Diagnostics business (Agilus) saw a sharp margin recovery to 23.1% from 14.4% in the corresponding previous quarter.
Net debt increased to ₹2,547 Cr (1.24x EBITDA) following the Agilus stake acquisition and Shrimann Hospital investment.
Acquired 125-bedded People Tree Hospital in Bengaluru for ₹430 Cr with potential to scale to 300+ beds.
💼 Action for Investors
Investors should focus on the strong operational EBITDA growth and significant margin expansion in the diagnostics segment. The inorganic expansion strategy in key clusters like Bengaluru and the recovery in Agilus provide a positive outlook for long-term value creation.
Fortis Q3 FY26: Revenue up 17.5% to ₹2,265 Cr; Operating EBITDA jumps 34.8%
Fortis Healthcare reported a strong operational performance for Q3 FY26, with consolidated revenues growing 17.5% YoY to INR 2,265 Cr. Operating EBITDA saw a significant jump of 34.8% to INR 505 Cr, driven by margin expansion in both hospital (21.7%) and diagnostic (23.1%) segments. While Profit After Tax fell 22.4% to INR 197 Cr due to a one-time exceptional loss related to new labor codes, Profit Before Tax (before exceptions) grew 21.9%. The company also strengthened its footprint through the INR 430 Cr acquisition of People Tree Hospital in Bengaluru.
Key Highlights
Consolidated Revenue grew 17.5% YoY to INR 2,265 Cr, with Hospital business contributing INR 1,938 Cr.
Operating EBITDA margins improved significantly to 22.3% from 19.4% in the previous year's quarter.
Diagnostics business (Agilus) showed a sharp recovery with EBITDA margins rising to 23.1% from 14.4%.
Net debt increased to INR 2,547 Cr (1.24x EBITDA) following acquisitions of Agilus PE stake and Shrimann Hospital.
Acquired 125-bedded People Tree Hospital in Bengaluru for INR 430 Cr to expand southern presence.
💼 Action for Investors
Investors should focus on the robust 34.8% growth in operating EBITDA and margin expansion rather than the exceptional-item-led PAT decline. The aggressive inorganic expansion in Bengaluru and recovery in the diagnostics segment are positive long-term indicators.
Fortis Healthcare Q3 Standalone Revenue Up 20.7% to ₹443 Cr; Board Approves 1.51 Cr ESOP Pool
Fortis Healthcare reported a standalone revenue of ₹442.93 crore for Q3 FY26, a 20.7% increase from ₹366.87 crore in the same quarter last year. However, standalone net profit for the quarter declined to ₹28.40 crore from ₹39.56 crore YoY, primarily due to a sharp rise in finance costs which reached ₹55.66 crore. The board has also approved a new Employee Stock Option Scheme (ESOP 2026) with a pool of 1.51 crore shares to attract and retain talent. Investors should remain aware of the ongoing SFIO investigations and legal matters regarding erstwhile promoters mentioned in the auditor's report.
Key Highlights
Standalone revenue from operations grew 20.7% YoY to ₹442.93 crore in Q3 FY26.
Standalone net profit decreased to ₹28.40 crore in Q3 FY26 compared to ₹39.56 crore in Q3 FY25.
Finance costs surged to ₹55.66 crore in the current quarter from ₹26.51 crore in the previous year's corresponding quarter.
Board approved ESOP 2026 scheme involving 1,50,99,163 equity shares, subject to shareholder approval.
Auditors maintained an emphasis of matter regarding ongoing SFIO investigations and Supreme Court orders related to RHT Health Trust.
💼 Action for Investors
Investors should monitor the consolidated financial performance to assess the impact of diagnostic and subsidiary segments. The increase in finance costs and the legal overhang from legacy promoter issues remain key monitorables.
Fortis Healthcare Q3 Standalone Revenue Up 20.7% YoY; Board Approves New ESOP Scheme
Fortis Healthcare reported a standalone revenue of ₹442.93 crore for Q3 FY26, marking a 20.7% growth over the same period last year. However, standalone net profit for the quarter saw a decline to ₹28.40 crore from ₹39.56 crore YoY, largely impacted by finance costs which more than doubled to ₹55.66 crore. For the nine-month period ended December 2025, the company's performance remains strong with a net profit of ₹205.37 crore compared to ₹106.02 crore in the previous year. Additionally, the board has approved a new ESOP scheme for 1.51 crore shares to align employee interests with shareholder value.
Key Highlights
Standalone Revenue from operations grew 20.7% YoY to ₹442.93 crore in Q3 FY26.
Net Profit for the quarter stood at ₹28.40 crore, down from ₹39.56 crore in the previous year's corresponding quarter.
Finance costs surged significantly to ₹55.66 crore in Q3 FY26 compared to ₹26.51 crore in Q3 FY25.
Board approved 'ESOP 2026' scheme covering 1,50,99,163 equity shares subject to shareholder approval.
Auditors highlighted ongoing legacy legal matters including SFIO investigations and Supreme Court observations on RHT Health Trust.
💼 Action for Investors
Investors should monitor the impact of rising finance costs on the bottom line and keep a close watch on the resolution of legacy legal and regulatory investigations. While the nine-month growth trajectory is positive, the quarterly profit dip suggests a need for cautious observation of operational margins.
Fortis Shareholders Approve Appointment of Mohd Shahazwan Bin Mohd Harris with 99.39% Majority
Fortis Healthcare shareholders have approved the appointment of Mr. Mohd Shahazwan Bin Mohd Harris as a Non-Independent & Non-Executive Director via postal ballot. The resolution saw high participation, with 86.73% of outstanding shares being polled. The appointment was passed with an overwhelming 99.39% majority, reflecting strong confidence from both promoters and institutional investors.
Key Highlights
Appointment of Mr. Mohd Shahazwan Bin Mohd Harris as Non-Executive Director approved.
Resolution received 650,781,446 votes in favour (99.39%) and 3,975,127 votes against (0.61%).
Promoter group supported the resolution with 100% of their 235.3 million votes.
Public institutional support was high at 98.96% out of 379.7 million votes polled.
💼 Action for Investors
This is a routine board appointment with high shareholder consensus; no immediate action is required.
Fortis Healthcare Receives NCLT Approval for Merger of Four Wholly-Owned Subsidiaries
Fortis Healthcare has received final NCLT approval to merge four of its wholly-owned subsidiaries—FESL, FCCL, FHMEL, and B&B—into Fortis Hospitals Limited (FHsL). The merger is effective from the appointed date of April 1, 2022, and is aimed at streamlining operations and reducing administrative overheads. As the entities involved are all wholly-owned subsidiaries, there will be no issuance of new shares or cash consideration, and the shareholding pattern of the listed parent remains unchanged. FHsL, the transferee company, reported a turnover of INR 12,824.21 million for the period ending March 31, 2025.
Key Highlights
NCLT Chandigarh and New Delhi have approved the merger of four subsidiaries into Fortis Hospitals Limited (FHsL).
The merger includes Fortis Emergency Services, Fortis Cancer Care, Fortis Health Management (East), and Birdie & Birdie Realtors.
The appointed date for the scheme is April 01, 2022, with FHsL reporting a turnover of INR 12,824.21 million in FY25.
No cash consideration or share issuance is involved as all entities are 100% owned within the group.
Rationale for the merger is to achieve cost rationalization and simplification of the management structure.
💼 Action for Investors
This is an internal corporate restructuring that simplifies the group structure without impacting consolidated financials or shareholding. Investors should view this as a positive step toward operational efficiency and reduced compliance costs.
Fortis Healthcare Receives NCLT Approval for Merger of Five Wholly-Owned Subsidiaries
Fortis Healthcare has received final NCLT approval for the merger of four wholly-owned subsidiaries (FESL, FCCL, FHMEL, and B&B) into Fortis Hospitals Limited (FHsL). The consolidation is designed to enhance operational efficiencies and reduce administrative and managerial overheads. As the entities are wholly-owned, there will be no issuance of new shares or cash consideration, ensuring no dilution for existing shareholders. The primary transferee, FHsL, reported a turnover of INR 12,824.21 million as of March 31, 2025.
Key Highlights
NCLT New Delhi and Chandigarh approved the scheme on Jan 5 and Jan 16, 2026, respectively.
The merger involves four subsidiaries being absorbed into Fortis Hospitals Limited (FHsL).
FHsL's turnover stood at INR 12,824.21 million with a paid-up capital of INR 799.88 million as of FY25.
The appointed date for the scheme is April 01, 2022, and it involves no share exchange or cash payout.
Restructuring aims to simplify management structure and achieve cost rationalization in financial reporting.
💼 Action for Investors
No immediate action is required as this is an internal consolidation with no impact on the listed entity's shareholding. Investors should monitor for long-term margin improvements resulting from reduced administrative costs.
Fortis Subsidiary Consummates Acquisition of TMI Healthcare Operations and Assets
Fortis Healthcare's wholly-owned subsidiary, International Hospital Limited (IHL), has successfully completed the acquisition of TMI Healthcare Private Limited. The transaction includes the hospital's operations along with the underlying land, building, and adjacent land parcels. This follows the definitive agreements previously entered into on December 20, 2025. The completion of this deal signifies Fortis's continued focus on expanding its physical infrastructure and service capacity.
Key Highlights
Wholly-owned subsidiary International Hospital Limited (IHL) finalized the acquisition on January 9, 2026.
Acquisition covers both hospital operations and the ownership of underlying land and buildings.
The transaction includes adjacent land, providing potential for future brownfield expansion.
Follows the initial disclosure of definitive agreements made on December 20, 2025.
💼 Action for Investors
Investors should view this as a positive expansion move and watch for the impact on bed capacity and operational margins in the next earnings cycle.
Fortis Healthcare Plans 3,200+ Bed Expansion by FY30; H1FY26 EBITDA Margin Hits 23.3%
Fortis Healthcare has outlined an aggressive expansion strategy to add over 3,200 beds by FY30, aiming for a total capacity of 8,061 beds. The company reported strong financial performance with H1FY26 consolidated revenue at INR 44,982 Mn and a significantly improved operating EBITDA margin of 23.3%. Hospital ARPOB grew 4.2% YoY to INR 24.9 Mn in H1FY26, while the diagnostics business maintained a healthy 24.6% margin. Key corporate milestones include the closure of the IHH Open Offer and the strategic acquisition of the 'Fortis' and 'SRL' brands.
Key Highlights
Planned addition of 3,200+ beds by FY30, targeting a total capacity of 8,061 beds representing a 10.7% CAGR.
H1FY26 consolidated operating EBITDA margin improved to 23.3%, up from 18.4% in FY25.
Hospital business ARPOB increased to INR 24.9 Mn in H1FY26, with overall occupancy steady at 70%.
Diagnostics business (Agilus) reported H1FY26 revenue of INR 7,684 Mn with a robust 24.6% EBITDA margin.
Maintain a strong balance sheet with Net Debt to Equity at 0.23x and Net Debt to TTM EBITDA at 1.15x as of Sep 2025.
💼 Action for Investors
Investors should look favorably on the clear 5-year expansion roadmap and the significant margin expansion achieved in H1FY26. The resolution of the IHH Open Offer and brand ownership issues removes major overhangs on the stock.
CRISIL Reaffirms Fortis Healthcare Ratings at AA+/Stable; Revenue Projected to Cross ₹10,000 Cr
CRISIL has reaffirmed Fortis Healthcare's long-term rating at 'AA+/Stable' and short-term rating at 'A1+', reflecting a strong business risk profile and improved operating efficiency. The company reported a 17% YoY revenue growth in H1 FY26 to ₹4,498 crore, with consolidated EBITDA margins expanding by 300 bps to 23.3%. Fortis is executing an aggressive expansion strategy, planning to add 1,200-1,500 beds by FY28, primarily through brownfield projects. Despite recent acquisitions like TMI Healthcare for ₹430 crore, the financial risk profile remains healthy with net debt/EBITDA projected to stay below 1.5x.
Key Highlights
CRISIL reaffirmed Long-Term rating at 'AA+/Stable' and Short-Term rating at 'A1+' for bank facilities and NCDs.
H1 FY26 consolidated revenue grew 17% YoY to ₹4,498 crore with EBITDA margins improving to 23.3%.
Planned addition of 1,200-1,500 beds between FY26 and FY28 to drive 10-12% revenue growth.
Gross debt expected to reach ₹3,400-3,500 crore by FY26-end following the TMI Healthcare acquisition.
Capital structure remains robust with gearing expected to stay below 0.6x in fiscal 2026.
💼 Action for Investors
Investors should take confidence in the rating reaffirmation which validates the company's strong cash flow and manageable debt levels despite aggressive expansion. Monitor the progress of brownfield bed additions and any final rulings on pending legacy litigations.
CRISIL Reaffirms Fortis Healthcare’s 'AA+/Stable' Rating; Revenue Set to Cross ₹10,000 Cr
CRISIL has reaffirmed Fortis Healthcare’s long-term rating at 'AA+/Stable', following a previous upgrade in September 2025. The company reported a strong H1 FY26 with revenue growing 17% YoY to ₹4,498 crore and EBITDA margins expanding to 23.3%. Fortis is executing an aggressive expansion plan to add 1,200-1,500 beds by FY28, supported by recent acquisitions like Shrimann Superspecialty and TMI Healthcare. Despite rising debt levels to approximately ₹3,400-3,500 crore for these acquisitions, the financial risk profile remains robust with gearing expected to stay below 0.6x.
Key Highlights
CRISIL reaffirmed 'AA+/Stable' rating for ₹1,550 crore NCDs and ₹425.98 crore bank facilities.
H1 FY26 consolidated revenue rose 17% YoY to ₹4,498 crore with EBITDA margins improving 300 bps to 23.3%.
Company plans to add 1,200-1,500 beds between FY26-FY28, primarily through brownfield expansions.
Net debt/EBITDA projected to remain healthy below 1.5x in FY26 despite ₹890 crore+ in recent acquisition commitments.
Medium-term operating margins are expected to sustain in the 22-25% range driven by better operating leverage.
💼 Action for Investors
Investors should take confidence in the rating reaffirmation which validates the company's improved operating efficiency and disciplined growth strategy. The stock remains a strong healthcare play as the company scales its bed capacity while maintaining a healthy balance sheet.